Camzyos treatment in real life: patient experiences
Treatments studied
Part of Heart & circulation clinical trials.
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You have been prescribed Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy
- You have agreed to join the study
- You have not been in a trial for any heart muscle inhibitor before
- You have taken Camzyos for 7 days or less at the time of the first survey
- You have not had a heart attack with bypass surgery in the last 3 months, or a stroke or mini-stroke in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This study tests whether adding the drug mavacamten to a heart procedure (radiofrequency ablation) helps people with a thickened heart muscle that blocks blood flow. It may reduce symptoms like chest pain or shortness of breath.
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This study looks at adults with a heart condition called obstructive hypertrophic cardiomyopathy. It tracks what happens after they start taking the medicine mavacamten, to learn more about its effects and how it works in real life.
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.